Genentech's Kadcyla meets in Phase III as breast cancer adjuvant

Genentech Inc. said adjuvant treatment with Kadcyla ado-trastuzumab emtansine met the primary endpoint of improving invasive disease-free survival

Read the full 188 word article

User Sign In